SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics' stock plummeted 25% following the final analysis of its HARMONi study for ivonescimab in non-small cell lung cancer, which revealed a significant disparity in progression-free survival (PFS) benefit between Asian (45% risk reduction) and Western (33% risk reduction) patients. This regional difference, coupled with the absence of a statistically significant overall survival (OS) benefit—a key FDA requirement for approval—raises substantial concerns regarding the drug's U.S. regulatory pathway and commercial viability, despite its lead in the competitive bispecific antibody market.

Analysis

Summit Therapeutics (SMMT) experienced a 25% share price decline following the release of the final analysis from its HARMONi study on ivonescimab for non-small cell lung cancer (NSCLC). The primary driver of this negative market reaction is the significant regional disparity in efficacy and a key regulatory setback. The study revealed a lower progression-free survival (PFS) benefit in Western patients, who saw a 33% risk reduction, compared to a 45% reduction in Asian patients, raising concerns about the drug's applicability and approval prospects in Western markets. More critically, the study failed to demonstrate a statistically significant overall survival (OS) benefit—a metric the FDA has indicated is required for marketing authorization in the United States. While the drug has shown promise in other studies, including outperforming Merck's Keytruda on PFS in the HARMONi-2 trial, and holds a developmental lead over competitors like BioNTech/Bristol Myers and Merck, these latest results introduce substantial uncertainty into its U.S. regulatory pathway. The stock's year-to-date gain of 9% now lags the industry's 12% growth, reflecting this newly priced-in risk.

Key Decisions for Investors

• Investors should recognize the substantially increased regulatory risk for ivonescimab's U.S. approval, as the lack of a statistically significant Overall Survival (OS) benefit in the HARMONi study presents a major hurdle with the FDA.
• Monitor for future data releases, particularly any mature OS data from the HARMONi study's Western patient cohort and primary results from the two other ongoing late-stage NSCLC studies, as these will be critical determinants for the drug's viability outside of China.
• Re-evaluate SMMT's first-mover advantage, as this setback could provide a window for competitors like Bristol Myers, BioNTech, and Merck to close the developmental gap with their own PD-1/VEGF targeting antibody candidates.
• Despite the 25% stock decline, a cautious or underweight stance is prudent until a clearer regulatory pathway emerges for Western markets, given the questions raised about data comparability between Asian and Western patient populations.